We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
-25.18%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
10 Year Est. Return
AUM
$195M
AUM Growth
+$18.4M
Cap. Flow
+$92M
Cap. Flow %
47.08%
Top 10 Hldgs %
100%
Holding
3
New
1
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$92M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DSGN icon
1
Design Therapeutics
DSGN
$915M
$90.9M 46.52%
5,626,476
ACLX
2
DELISTED
Arcellx
ACLX
$77.1M 39.48%
+5,500,007
New +$92M
EFTR
3
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$27.4M 14.01%
272,885

Similar funds

SR One Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, SR One Capital Management held 3 positions worth $195M, up 10% from $177M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

SR One Capital Management deployed $92M of net new capital in Q1 2022, opening 1 new position. Its largest new stake was Arcellx: 5,500,007 shares worth $77.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SR One Capital Management's largest Q1 2022 buy was Arcellx: 5,500,007 shares worth $77.1M.
  • SR One Capital Management's ten largest holdings make up 100% of its $195M portfolio in Q1 2022.
  • SR One Capital Management opened 1 new position and closed 0 in Q1 2022.
  • SR One Capital Management's portfolio value rose 10% quarter-over-quarter to $195M.

Based on SR One Capital Management's 13F filing for Q1 2022, filed 10 May 2022.